| Product Unit Size | Cost | Quantity | Stock |
|---|
Dinaciclib inhibits CDK1/2/5/9, displaying anticancer chemotherapeutic activity. Dinaciclib is currently in clinical trials as a potential treatment for various cancers. In cellular models of acute leukemias, dinaciclib inhibits cell proliferation. In cellular models of pancreatic cancer, this compound inhibits cell proliferation, motility, and colony formation; in vivo, it decreases tumor growth. Dinaciclib also binds BRD proteins.
| Cas No. | 779353-01-4 |
|---|---|
| Purity | ≥99% |
| Formula | C21H28N6O2 |
| Formula Wt. | 396.49 |
| IUPAC Name | 2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol |
| Synonym | SCH 727965 |
| Solubility | DMSO 26 mg/mL warmed (65.57 mM) Ethanol 8 mg/mL warmed (20.17 mM) Water Insoluble |
| Appearance | Yellow to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Flynn J, Jones J, Johnson AJ, et al. Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print]. PMID: 25708835.
Martin MP, Olesen SH, Georg GI, et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol. 2013 Nov 15;8(11):2360-5. PMID: 24007471.
Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. PMID: 23949430.
Feldmann G, Mishra A, Bisht S, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. PMID: 21768779.